Therapeutic implications of glycogen synthase kinase-3β in Alzheimer’s disease: a novel therapeutic target

References

• Heemels MT. Neurodegenerative diseases. Nature. 2016;539(7628):179–180.
   PubMed Web of Science ®Google Scholar
• Akhtar MN, Lam KW, Abas F, et al. New class of acetylcholinesterase inhibitors from the stem bark of Knemalaurina and their structural insights. Bioorg Med Chem Lett. 2011;21(13):4097–4103.
   PubMed Web of Science ®Google Scholar
• Abeliovich A, Gitler AD. Defects in trafficking bridge Parkinson’s disease pathology and genetics. Nature. 2016;539(7628):207–216.
   PubMed Web of Science ®Google Scholar
• Canter RG, Penney J, Tsai LH. The road to restoring neural circuits for the treatment of Alzheimer’s disease. Nature. 2016;539(7628):187–196.
   PubMed Web of Science ®Google Scholar
• Taylor JP, Brown RH, Cleveland DW. Decoding ALS: from genes to mechanism. Nature. 2016;539(7628):197–206.
   PubMed Web of Science ®Google Scholar
• Wyss-Coray T. Ageing, neurodegeneration and brain rejuvenation. Nature. 2016;539(7628):180–186.
   PubMed Web of Science ®Google Scholar
• Kennedy DO, Dodd FL, Robertson BC, et al. Monoterpenoid extract of sage (Salvia lavandulaefolia) with cholinesterase inhibiting properties improves cognitive performance and mood in healthy adults. J Psychopharmacol. 2011;25(8):1088–1100.
   PubMed Web of Science ®Google Scholar
• Mariani E, Polidori MC, Cherubini A, et al. Oxidative stress in brain aging, neurodegenerative and vascular diseases: an overview. J Chromatogr B Analyt Technol Biomed Life Sci. 2005;827(1):65–75.
   PubMed Web of Science ®Google Scholar
• Valko M, Leibfritz D, Moncol J, et al. Free radicals and antioxidants in normal physiological functions and human disease. Int J Biochem Cell Biol. 2007;39(1):44–84.
   PubMed Web of Science ®Google Scholar
• Goedert M, Spillantini MG. A century of Alzheimer’s disease. Science. 2006;314(5800):777–781.
   PubMed Web of Science ®Google Scholar
• Patterson C. World Alzheimer report. The State of the Art of Dementia Research: N Front. 2018;2018.
   Google Scholar
• dos Santos Pisoni D, da Costa JS, Gamba D, et al. Synthesis and AChE inhibitory activity of new chiral tetrahydroacridine analogues from terpeniccyclanones. Eur J Med Chem. 2010;45(2):526–535.
   PubMed Web of Science ®Google Scholar
• Bagyinszky E, Youn YC, An SS, et al. The genetics of Alzheimer’s disease. Clin Interv Aging. 2014;9:535–551.
   PubMed Web of Science ®Google Scholar
• Kasper KP. Bioinorganic chemistry of Alzheimer’s disease. Chem Rev. 2012;112:5193–5239.
   PubMed Web of Science ®Google Scholar
• Yin KJ, Cirrito JR, Yan P, et al. Matrix metalloproteinases expressed by astrocytes mediate extracellular amyloid-β peptide catabolism. J Neurosci. 2006;26(43):10939–10948.
   PubMed Web of Science ®Google Scholar
• Iqbal K, Grundke-Iqbal I. Alzheimer neurofibrillary degeneration: significance, etiopathogenesis, therapeutics and prevention. J Cell Mol Med. 2008;12(1):38–55.
   PubMed Web of Science ®Google Scholar
• Mudher M, Lovestone S. Alzheimer’s disease- do tauists and baptists finally shake hands? Trends Neurosci. 2002;25(1):22–26.
   PubMed Web of Science ®Google Scholar
• Moore AH, O'Banion MK. Neuroinflammation and anti-inflammatory therapy for Alzheimer’s disease. Adv Drug Deliv Rev. 2002;54(12):1627–1656.
   PubMed Web of Science ®Google Scholar
• Ballatore C, Lee VM-Y, Trojanowski JQ. Tau-mediated neurodegeneration in Alzheimer’s disease and related disorders. Nat Rev Neurosci. 2007;8(9):663–672.
   PubMed Web of Science ®Google Scholar
• de La Torre JC. Vascular basis of Alzheimer’s pathology. Ann N Y Acad Sci. 2002;977:196–215.
   PubMed Web of Science ®Google Scholar
• Bonda DJ, Wang X, Perry G, et al. Oxidative stress in Alzheimer disease: a possibility for prevention. Neuropharmacol. 2010;59(4–5):290–294.
   PubMed Web of Science ®Google Scholar
• Dumont M, Beal MF. Neuroprotective strategies involving ROS in Alzheimer disease. Free Radic Biol Med. 2011;51(5):1014–1026.
   PubMed Web of Science ®Google Scholar
• Finkel T, Holbrook NJ. Oxidants, oxidative stress and the biology of ageing. Nature. 2000;408(6809):239–247.
   PubMed Web of Science ®Google Scholar
• Obulesu M, Venu R, Somashekhar R. Lipid peroxidation in Alzheimer’s disease: emphasis on metal-mediated neurotoxicity. Acta Neurol Scand. 2011;124(5):295–301.
   PubMed Web of Science ®Google Scholar
• Bush AI, Tanzi RE. Therapeutics for Alzheimer’s disease based on the metal hypothesis. Neurotherapeutics. 2008;5(3):421–432.
   PubMed Web of Science ®Google Scholar
• Samudralwar DL, Diprete CC, Ni BF, et al. Elemental imbalances in the olfactory pathway in Alzheimer’s disease. J Neurol Sci. 1995;130(2):139–145.
   PubMed Web of Science ®Google Scholar
• Zatta P, Drago D, Bolognin S, et al. Alzheimer’s disease, metal ions and metal homeostatic therapy. Trends Pharmacol Sci. 2009;30(7):346–355.
   PubMed Web of Science ®Google Scholar
• Schrag M, Crofton A, Zabel M, et al. Effect of cerebral amyloid angiopathy on brain iron, copper, and zinc in Alzheimer’s disease. J Alzheimers Dis. 2011;24(1):137–149.
   PubMed Web of Science ®Google Scholar
• Rulon LL, Robertson JD, Lovell MA, et al. Serum zinc levels and Alzheimer’s disease. Biol Trace Elem Res. 2000;75(1–3):79–85.
   PubMed Web of Science ®Google Scholar
• Panayi AE, Spyrou NM, Iversen BS, et al. Determination of cadmium and zinc in Alzheimer’s brain tissue using inductively coupled plasma mass spectrometry. J Neurol Sci. 2002;195(1):1–10.
   PubMed Web of Science ®Google Scholar
• de Jong LW, van der Hiele K, Veer IM, et al. Strongly reduced volumes of putamen and thalamus in Alzheimer’s disease: an MRI study. Brain. 2008;131(Pt 12):3277–3285.
   PubMed Web of Science ®Google Scholar
• Talmard C, Yona RL, Faller P. Mechanism of zinc (II)-promoted amyloid formation: zinc (II) binding facilitates the transition from the partially α-helical conformer to aggregates of amyloid β protein (1-28). J Biol Inorg Chem. 2009;14(3):449–455.
   PubMed Web of Science ®Google Scholar
• Sengupta P, Garai K, Sahoo B, et al. The amyloid β peptide (Aβ1-40) is thermodynamically soluble at physiological concentrations. Biochemistry. 2003;42(35):10506–10513.
   PubMed Web of Science ®Google Scholar
• Tougu V, Karafin A, Zovo K, et al. Zinc (II)- and copper (II)-induced nonfibrillar aggregates of amyloid-beta (1-42) peptide are transformed to amyloid fibrils, both spontaneously and under the influence of metal chelators. J Neurochem. 2009;110(6):1784–1795.
   PubMed Web of Science ®Google Scholar
• Pedersen JT, Teilum K, Heegaard NH, et al. Rapid formation of a preoligomeric peptide–metal–peptide complex following copper (II) binding to amyloid β peptides. Angew Chem. 2011;123(11):2580–2583.
   Google Scholar
• Schellenberg GD, Bird TD, Wijsman EM, et al. Genetic linkage evidence for a familial Alzheimer’s disease locus on chromosome 14. Science. 1992;258(5082):668–671.
   PubMed Web of Science ®Google Scholar
• Finckh U, Alberici A, Antoniazzi M, et al. Variable expression of familial Alzheimer disease associated with presenilin 2 mutation M239I. Neurology. 2000;54(10):2006–2008.
   PubMed Web of Science ®Google Scholar
• Drachman DA, Leavitt J. Human memory and the cholinergic system: a relationship to aging? Arch Neurol. 1974;30(2):113–121.
   PubMed Web of Science ®Google Scholar
• Bartus RT, Dean RL, Beer B, et al. The cholinergic hypothesis of geriatric memory dysfunction. Science. 1982;217(4558):408–414.
   PubMed Web of Science ®Google Scholar
• Gholivand K, Hosseini Z, Farshadian S, et al. Synthesis, characterization, oxidative degradation, antibacterial activity and acetylcholinesterase/butyrylcholinesterase inhibitory effects of some new phosphorus (V) hydrazides. Eur J Med Chem. 2010;45(11):5130–5139.
   PubMed Web of Science ®Google Scholar
• Hooper C, Killick R, Lovestone S. The GSK3 hypothesis of Alzheimer’s disease. J Neurochem. 2008;104(6):1433–1439.
   PubMed Web of Science ®Google Scholar
• Mobashir M, Madhusudhan T, Isermann B, et al. Negative interactions and feedback regulations are required for transient cellular response. Sci Rep. 2014;4(1):3718.
   PubMed Web of Science ®Google Scholar
• Mobashir M, Schraven B, Beyer T. Simulated evolution of signal transduction networks. PLoS One. 2012;7(12):e50905.
   PubMed Web of Science ®Google Scholar
• de la Monte SM, Tong M, Lester-Coll N, et al. Therapeutic rescue of neurodegeneration in experimental type 3 diabetes: relevance to Alzheimer’s disease. J Alzheimers Dis. 2006;10(1):89–109.
   PubMed Web of Science ®Google Scholar
• Wang H, Brown J, Martin M. Glycogen synthase kinase 3: a point of convergence for the host inflammatory response. Cytokine. 2011;53(2):130–140.
   PubMed Web of Science ®Google Scholar
• McCubrey JA, Steelman LS, Bertrand FE, et al. GSK-3 as potential target for therapeutic intervention in cancer. Oncotarget. 2014;5(10):2881–2911.
   PubMedGoogle Scholar
• Shimura T. Acquired radioresistance of cancer and the AKT/GSK3β/cyclin D1 overexpression cycle. J Radiat Res. 2011;52(5):539–544.
   PubMed Web of Science ®Google Scholar
• Woodgett JR. Molecular cloning and expression of glycogen synthase kinase-3/factor A. EMBO J. 1990;9(8):2431–2438.
   PubMed Web of Science ®Google Scholar
• Lee SJ, Chung YH, Joo KM, et al. Age-related changes in glycogen synthase kinase 3β (GSK3β) immunoreactivity in the Central nervous system of rats. Neurosci Lett. 2006;409(2):134–139.
   PubMed Web of Science ®Google Scholar
• Leroy K, Yilmaz Z, Brion JP. Increased level of active GSK-3β in Alzheimer’s disease and accumulation in argyrophilic grains and in neurones at different stages of neurofibrillary degeneration. Neuropath App Neurobiol. 2007;33(1):43–55.
   PubMed Web of Science ®Google Scholar
• Llorens-Martín M, López-Doménech G, Soriano E, et al. GSK3β is involved in the relief of mitochondria pausing in a tau-dependent manner. PLoS One. 2011;6(11):e27686.
   PubMed Web of Science ®Google Scholar
• Fang X, Yu SX, Lu Y, et al. Phosphorylation and inactivation of glycogen synthase kinase 3 by protein kinase A. Proc Natl Acad Sci USA. 2000;97(22):11960–11965.
   PubMed Web of Science ®Google Scholar
• Ali A, Hoeflich KP, Woodgett JR. Glycogen synthase kinase-3: properties, functions, and regulation. Chem Rev. 2001;101(8):2527–2540.
   PubMed Web of Science ®Google Scholar
• Eldar-Finkelman H. Glycogen synthase kinase 3: an emerging therapeutic target. Trends Mol Med. 2002;8(3):126–132.
   PubMed Web of Science ®Google Scholar
• Sharfi H, Eldar-Finkelman H. Sequential phosphorylation of insulin receptor substrate-2 by glycogen synthase kinase-3 and c-Jun NH2-terminal kinase plays a role in hepatic insulin signaling. Am J Physiol Endocrinol Metab. 2008;294(2):E307–E315.
   PubMed Web of Science ®Google Scholar
• Angers S, Moon RT. Proximal events in Wnt signal transduction. Nat Rev Mol Cell Biol. 2009;10(7):468–477.
   PubMed Web of Science ®Google Scholar
• Liu C, Li Y, Semenov M, et al. Control of β-catenin phosphorylation/degradation by a dual-kinase mechanism. Cell. 2002;108(6):837–847.
   PubMed Web of Science ®Google Scholar
• Bhat RV, Budd Haeberlein SL, Avila J, et al. Glycogen synthase kinase 3: a drug target for CNS therapies. J Neurochem. 2004;89(6):1313–1317.
   PubMed Web of Science ®Google Scholar
• Hernández F, Pérez M, Lucas JJ, et al. Glycogen synthase kinase-3 plays a crucial role in tau exon 10 splicing and intranuclear distribution of SC35: implications for Alzheimer’s disease. J Biol Chem. 2004;279(5):3801–3806.
   PubMed Web of Science ®Google Scholar
• Fulga TA, Elson-Schwab I, Khurana V, et al. Abnormal bundling and accumulation of F-actin mediates tau-induced neuronal degeneration in vivo. Nat Cell Biol. 2007;9(2):139–148.
   PubMed Web of Science ®Google Scholar
• Cohen P, Goedert M. GSK3 inhibitors: development and therapeutic potential. Nat Rev Drug Discov. 2004;3(6):479–487.
   PubMed Web of Science ®Google Scholar
• Kozikowski AP, Gaisina IN, Petukhov PA, et al. Highly potent and specific GSK-3β inhibitors that block tau phosphorylation and decrease α-synuclein protein expression in a cellular model of Parkinson’s disease. Chem Med Chem: Chem Enabling Drug Discov. 2006;1(2):256–266.
   Web of Science ®Google Scholar
• Emamian ES, Hall D, Birnbaum MJ, et al. Convergent evidence for impaired AKT1-GSK3β signaling in schizophrenia. Nat Genet. 2004;36(2):131–137.
   PubMed Web of Science ®Google Scholar
• Klein PS, Melton DA. A molecular mechanism for the effect of lithium on development. Proc Natl Acad Sci USA. 1996;93(16):8455–8459.
   PubMed Web of Science ®Google Scholar
• Richard SJ, Johnson GVW. The glamour and gloom of glycogen synthase kinase-3. Trends Biochem Sci. 2004;29(2):95–102.
   PubMed Web of Science ®Google Scholar
• Cole AR, Knebel A, Morrice NA, et al. GSK-3 phosphorylation of the Alzheimer epitope within collapsin response mediator proteins regulates axon elongation in primary neurons. J Biol Chem. 2004;279(48):50176–50180.
   PubMed Web of Science ®Google Scholar
• Jiang H, Guo W, Liang X, et al. Both the establishment and the maintenance of neuronal polarity require active mechanisms: critical roles of GSK-3β and its upstream regulators. Cell. 2005;120(1):123–135.
   PubMed Web of Science ®Google Scholar
• Yoshimura T, Kawano Y, Arimura N, et al. GSK-3β regulates phosphorylation of CRMP-2 and neuronal polarity. Cell. 2005;120(1):137–149.
   PubMed Web of Science ®Google Scholar
• Lovestone S, Reynolds CH, Latimer D, et al. Alzheimer’s disease-like phosphorylation of the microtubule-associated protein tau by glycogen synthase kinase-3 in transfected mammalian cells. Curr Biol. 1994;4(12):1077–1086.
   PubMed Web of Science ®Google Scholar
• Hanger DP, Hughes K, Woodgett JR, et al. Glycogen synthase kinase-3 induces Alzheimer’s disease-like phosphorylation of tau: generation of paired helical filament epitopes and neuronal localisation of the kinase. Neurosci Lett. 1992;147(1):58–62.
   PubMed Web of Science ®Google Scholar
• Goedert M, Jakes R, Crowther RA, et al. Epitope mapping of monoclonal antibodies to the paired helical filaments of Alzheimer’s disease: identification of phosphorylation sites in tau protein. Biochem J. 1994;301(3):871–877.
   PubMed Web of Science ®Google Scholar
• Hasegawa M, Jakes R, Crowther RA, et al. Characterization of mAb AP422, a novel phosphorylation-dependent monoclonal antibody against tau protein. FEBS Lett. 1996;384(1):25–30.
   PubMed Web of Science ®Google Scholar
• Hong M, Chen DC, Klein PS, et al. Lithium reduces tau phosphorylation by inhibition of glycogen synthase kinase-3. J Biol Chem. 1997;272(40):25326–25332.
   PubMed Web of Science ®Google Scholar
• Palacino JJ, Murphy MP, Murayama O, et al. Presenilin 1 regulates β-catenin-mediated transcription in a glycogen synthase kinase-3-independent fashion. J Biol Chem. 2001;276(42):38563–38569.
   PubMed Web of Science ®Google Scholar
• Phiel CJ, Wilson CA, Lee VM, et al. GSK-3α regulates production of Alzheimer’s disease amyloid-β peptides. Nature. 2003;423(6938):435–439.
   PubMed Web of Science ®Google Scholar
• Alvarez G, Muñoz-Montaño JR, Satrústegui J, et al. Lithium protects cultured neurons against β-amyloid-induced neurodegeneration. FEBS Lett. 1999;453(3):260–264.
   PubMed Web of Science ®Google Scholar
• Morales-Garcia JA, Luna-Medina R, Alonso-Gil S, et al. Glycogen synthase kinase 3 inhibition promotes adult hippocampal neurogenesis in vitro and in vivo. ACS Chem Neurosci. 2012;3(11):963–971.
   PubMed Web of Science ®Google Scholar
• Dunning CJ, McGauran G, Willén K, et al. Direct high affinity interaction between Aβ42 and GSK3α stimulates hyperphosphorylation of tau. A new molecular link in Alzheimer’s disease? ACS Chem Neurosci. 2016;7(2):161–170.
   PubMed Web of Science ®Google Scholar
• Koike H, Tomioka S, Sorimachi H, et al. Membrane-anchored metalloprotease MDC9 has an alpha-secretase activity responsible for processing the amyloid precursor protein. Biochem J. 1999;343(2):371–375.
   PubMed Web of Science ®Google Scholar
• Cai Z, Zhao Y, Zhao B. Roles of glycogen synthase kinase 3 in Alzheimer’s disease. Curr Alzheimer Res. 2012;9(7):864–879.
   PubMed Web of Science ®Google Scholar
• Uemura K, Kuzuya A, Shimozono Y, et al. GSK3β activity modifies the localization and function of presenilin 1. J Biol Chem. 2007;282(21):15823–15832.
   PubMed Web of Science ®Google Scholar
• Ly PT, Wu Y, Zou H, et al. Inhibition of GSK3β-mediated BACE1 expression reduces Alzheimer-associated phenotypes. J Clin Invest. 2013;123(1):224–235.
   PubMed Web of Science ®Google Scholar
• Chen CH, Zhou W, Liu S, et al. Increased NF-κB signalling up-regulates BACE1 expression and its therapeutic potential in Alzheimer’s disease. Int J Neuropsychopharmacol. 2012;15(1):77–90.
   PubMed Web of Science ®Google Scholar
• Luo Y, Bolon B, Kahn S, et al. Mice deficient in BACE1, the Alzheimer’s β-secretase, have normal phenotype and abolished β-amyloid generation. Nat Neurosci. 2001;4(3):231–232.
   PubMed Web of Science ®Google Scholar
• Sun X, Sato S, Murayama O, et al. Lithium inhibits amyloid secretion in COS7 cells transfected with amyloid precursor protein. C100. Neurosci Lett. 2002;321(1–2):61–64.
   PubMed Web of Science ®Google Scholar
• Farris W, Mansourian S, Chang Y, et al. Insulin-degrading enzyme regulates the levels of insulin, amyloid β-protein, and the β-amyloid precursor protein intracellular domain in vivo. Proc Natl Acad Sci USA. 2003;100(7):4162–4167.
   PubMed Web of Science ®Google Scholar
• Magdesian MH, Carvalho MM, Mendes FA, et al. Amyloid-β binds to the extracellular cysteine-rich domain of frizzled and inhibits Wnt/β-catenin signaling. J Biol Chem. 2008;283(14):9359–9368.
   PubMed Web of Science ®Google Scholar
• Hernández F, de Barreda EG, Fuster-Matanzo A, et al. GSK3: a possible link between beta amyloid peptide and tau protein. Exp Neurol. 2010;223(2):322–325.
   PubMed Web of Science ®Google Scholar
• Andreadis A. Tau gene alternative splicing: expression patterns, regulation and modulation of function in normal brain and neurodegenerative diseases. Biochim Biophys Acta. 2005;1739(2–3):91–103.
   PubMed Web of Science ®Google Scholar
• Martin L, Latypova X, Terro F. Post-translational modifications of tau protein: implications for Alzheimer’s disease. Neurochem Int. 2011;58(4):458–471.
   PubMed Web of Science ®Google Scholar
• Asuni AA, Hooper C, Reynolds CH, et al. GSK3α exhibits β-catenin and tau directed kinase activities that are modulated by Wnt. Eur J Neurosci. 2006;24(12):3387–3392.
   PubMed Web of Science ®Google Scholar
• Lucas JJ, Hernández F, Gómez-Ramos P, et al. Decreased nuclear β-catenin, tau hyperphosphorylation and neurodegeneration in GSK-3β conditional transgenic mice. EMBO J. 2001;20(1–2):27–39.
   PubMed Web of Science ®Google Scholar
• Engel T, Goñi-Oliver P, Lucas JJ, et al. Chronic lithium administration to FTDP-17 tau and GSK-3β overexpressing mice prevents tau hyperphosphorylation and neurofibrillary tangle formation, but pre-formed neurofibrillary tangles do not revert. J Neurochem. 2006;99(6):1445–1455.
   PubMed Web of Science ®Google Scholar
• Mudher A, Shepherd D, Newman TA, et al. GSK-3 β inhibition reverses axonal transport defects and behavioural phenotypes in drosophila. Mol Psychiatry. 2004;9(5):522–530.
   PubMed Web of Science ®Google Scholar
• Lesort M, Jope RS, Johnson GV. Insulin transiently increases tau phosphorylation: Involvement of glycogen synthase kinase-3β and fyn tyrosine kinase. J Neurochem. 1999;72(2):576–584.
   PubMed Web of Science ®Google Scholar
• Caricasole A, Copani A, Caraci F, et al. Induction of dickkopf-1, a negative modulator of the Wnt pathway, is associated with neuronal degeneration in Alzheimer’s brain. J Neurosci. 2004;24(26):6021–6027.
   PubMed Web of Science ®Google Scholar
• Takashima A, Murayama M, Murayama O, et al. Presenilin 1 associates with glycogen synthase kinase-3β and its substrate tau. Proc Natl Acad Sci USA. 1998;95(16):9637–9641.
   PubMed Web of Science ®Google Scholar
• Baki L, Shioi J, Wen P, et al. PS1 activates PI3K thus inhibiting GSK-3 activity and tau over phosphorylation: effects of FAD mutations. EMBO J. 2004;23(13):2586–2596.
   PubMed Web of Science ®Google Scholar
• Giese KP. GSK-3: a key player in neurodegeneration and memory. IUBMB Life. 2009;61(5):516–521.
   PubMed Web of Science ®Google Scholar
• Peineau S, Taghibiglou C, Bradley C, et al. LTP inhibits LTD in the hippocampus via regulation of GSK3β. Neuron. 2007;53(5):703–717.
   PubMed Web of Science ®Google Scholar
• Hooper C, Markevich V, Plattner F, et al. Glycogen synthase kinase-3 inhibition is integral to long-term potentiation. Eur J Neurosci. 2007;25(1):81–86.
   PubMed Web of Science ®Google Scholar
• Hui J, Zhang J, Pu M, et al. Modulation of GSK-3β/β-catenin signaling contributes to learning and memory impairment in a rat model of depression. Int J Neuropsychopharmacol. 2018;21(9):858–870.
   PubMed Web of Science ®Google Scholar
• Maguschak KA, Ressler KJ. β-catenin is required for memory consolidation. Nat Neurosci. 2008;11(11):1319–1326.
   PubMed Web of Science ®Google Scholar
• Vallée A, Lecarpentier Y. Alzheimer disease: crosstalk between the canonical Wnt/beta-catenin pathway and PPARs alpha and gamma. Front Neurosci. 2016;10:459.
   PubMed Web of Science ®Google Scholar
• Llorens-Martín M, Jurado J, Hernández F, et al. GSK-3β, a pivotal kinase in Alzheimer disease. Front Mol Neurosci. 2014;7(46):46.
   PubMed Web of Science ®Google Scholar
• Onishi T, Iwashita H, Uno Y, et al. A novel glycogen synthase kinase-3 inhibitor 2-methyl-5-(3-{4-[(S)-methylsulfinyl] phenyl}-1-benzofuran-5-yl)-1, 3, 4-oxadiazole decreases tau phosphorylation and ameliorates cognitive deficits in a transgenic model of Alzheimer’s disease. J Neurochem. 2011;119(6):1330–1340.
   PubMed Web of Science ®Google Scholar
• Avrahami L, Farfara D, Shaham-Kol M, et al. Inhibition of glycogen synthase kinase-3 ameliorates β-amyloid pathology and restores lysosomal acidification and mammalian target of rapamycin activity in the Alzheimer disease mouse model: in vivo and in vitro studies. J Biol Chem. 2013;288(2):1295–1306.
   PubMed Web of Science ®Google Scholar
• Sirerol-Piquer M, GomezRamos P, Hernández F, et al. GSK3β overexpression induces neuronal death and a depletion of the neurogenic niches in the dentate gyrus. Hippocampus. 2011;21(8):910–922.
   PubMed Web of Science ®Google Scholar
• Zhao C, Deng W, Gage FH. Mechanisms and functional implications of adult neurogenesis. Cell. 2008;132(4):645–660.
   PubMed Web of Science ®Google Scholar
• Moreno-Jiménez EP, Flor-García M, Terreros-Roncal J, et al. Adult hippocampal neurogenesis is abundant in neurologically healthy subjects and drops sharply in patients with Alzheimer’s disease. Nat Med. 2019;25(4):554–560.
   PubMed Web of Science ®Google Scholar
• Goodenough S, Schleusner D, Pietrzik C, et al. Glycogen synthase kinase 3β links neuroprotection by 17β-estradiol to key Alzheimer processes. Neurosci. 2005;132(3):581–589.
   PubMed Web of Science ®Google Scholar
• Preece P, Virley DJ, Costandi M, et al. β-Secretase (BACE) and GSK-3 mRNA levels in Alzheimer’s disease. Mol Brain Res. 2003;116(1–2):155–158.
   PubMedGoogle Scholar
• Michelucci A, Heurtaux T, Grandbarbe L, et al. Characterization of the microglial phenotype under specific pro-inflammatory and anti-inflammatory conditions: effects of oligomeric and fibrillar amyloid-β. J Neuroimmunol. 2009;210(1–2):3–12.
   PubMed Web of Science ®Google Scholar
• Heneka MT, O'Banion MK, Terwel D, et al. Neuroinflammatory processes in Alzheimer’s disease. J Neural Transm (Vienna). 2010;117(8):919–947.
   PubMed Web of Science ®Google Scholar
• Koistinaho J, Malm T, Goldsteins G. Glycogen synthase kinase-3β: a mediator of inflammation in Alzheimer’s disease? Int J Alzheimers Dis. 2011;2011:129753.
   PubMedGoogle Scholar
• Beurel E, Jope RS. Differential regulation of STAT family members by glycogen synthase kinase-3. J Biol Chem. 2008;283(32):21934–21944.
   PubMed Web of Science ®Google Scholar
• Yuskaitis CJ, Jope RS. Glycogen synthase kinase-3 regulates microglial migration, inflammation, and inflammation-induced neurotoxicity. Cell Signal. 2009;21(2):264–273.
   PubMed Web of Science ®Google Scholar
• Plotkin B, Kaidanovich O, Talior I, et al. Insulin mimetic action of synthetic phosphorylated peptide inhibitors of glycogen synthase kinase-3. J Pharmacol Exp Ther. 2003;305(3):974–980.
   PubMed Web of Science ®Google Scholar
• Samadi A, Valderas C, de los Ríos C, et al. Cholinergic and neuroprotective drugs for the treatment of Alzheimer and neuronal vascular diseases. II. Synthesis, biological assessment, and molecular modelling of new tacrine analogues from highly substituted 2-aminopyridine-3-carbonitriles. Bioorg Med Chem. 2011;19(1):122–133.
   PubMed Web of Science ®Google Scholar
• Wang H, Wang R, Zhao Z, et al. Coexistences of insulin signaling-related proteins and choline acetyltransferase in neurons. Brain Res. 2009;1249:237–243.
   PubMed Web of Science ®Google Scholar
• Kokubo H, Kayed R, Glabe CG, et al. Soluble Aβ oligomers ultrastructurally localize to cell processes and might be related to synaptic dysfunction in Alzheimer’s disease brain. Brain Res. 2005;1031(2):222–228.
   PubMed Web of Science ®Google Scholar
• Robert M, Mathuranath PS. Tau and tauopathies. Neurol India. 2007;55(1):11–16.
   PubMed Web of Science ®Google Scholar
• Zumbrunn J, Kinoshita K, Hyman AA, et al. Binding of the adenomatous polyposis coli protein to microtubules increases microtubule stability and is regulated by GSK3β phosphorylation. Curr Biol. 2001;11(1):44–49.
   PubMed Web of Science ®Google Scholar
• Sergeant N, Bretteville A, Hamdane M, et al. Biochemistry of tau in Alzheimer’s disease and related neurological disorders. Expert Rev Proteomics. 2008;5(2):207–224.
   PubMed Web of Science ®Google Scholar
• Rauk A. Why is the amyloid beta peptide of Alzheimer’s disease neurotoxic? Dalton Trans. 2008;(10):1273–1282.
   PubMed Web of Science ®Google Scholar
• Pope W, Enam SA, Bawa N, et al. Phosphorylated tau epitope of Alzheimer’s disease is coupled to axon development in the avian Central nervous system. Exp Neurol. 1993;120(1):106–113.
   PubMed Web of Science ®Google Scholar
• Bartzokis G, Cummings JL, Sultzer D, et al. White matter structural integrity in healthy aging adults and patients with Alzheimer disease: a magnetic resonance imaging study. Arch Neurol. 2003;60(3):393–398.
   PubMed Web of Science ®Google Scholar
• Montenegro-Venegas C, Tortosa E, Rosso S, et al. MAP1B regulates axonal development by modulating Rho-GTPase Rac1 activity. Mol Biol Cell. 2010;21(20):3518–3528.
   PubMed Web of Science ®Google Scholar
• Soutar MP, Kim WY, Williamson R, et al. Evidence that glycogen synthase kinase-3 isoforms have distinct substrate preference in the brain. J Neurochem. 2010;115(4):974–983.
   PubMed Web of Science ®Google Scholar
• Ryan KA, Pimplikar SW. Activation of GSK-3 and phosphorylation of CRMP2 in transgenic mice expressing APP intracellular domain. J Cell Biol. 2005;171(2):327–335.
   PubMed Web of Science ®Google Scholar
• Pigino G, Morfini G, Pelsman A, et al. Alzheimer’s presenilin 1 mutations impair kinesin-based axonal transport. J Neurosci. 2003;23(11):4499–4508.
   PubMed Web of Science ®Google Scholar
• Beurel E, Jope RS. The paradoxical pro-and anti-apoptotic actions of GSK3 in the intrinsic and extrinsic apoptosis signaling pathways. Prog Neurobiol. 2006;79(4):173–189.
   PubMed Web of Science ®Google Scholar
• Johnson-Farley NN, Travkina T, Cowen DS. Cumulative activation of akt and consequent inhibition of glycogen synthase kinase-3 by brain-derived neurotrophic factor and insulin-like growth factor-1 in cultured hippocampal neurons. J Pharmacol Exp Ther. 2006;316(3):1062–1069.
   PubMed Web of Science ®Google Scholar
• Watcharasit P, Bijur GN, Song L, et al. Glycogen synthase kinase-3β (GSK3β) binds to and promotes the actions of p53. J Biol Chem. 2003;278(49):48872–48879.
   PubMed Web of Science ®Google Scholar
• Loberg RD, Vesely E, Brosius FC. Enhanced glycogen synthase kinase-3β activity mediates hypoxia-induced apoptosis of vascular smooth muscle cells and is prevented by glucose transport and metabolism. J Biol Chem. 2002;277(44):41667–41673.
   PubMed Web of Science ®Google Scholar
• Bijur GN, De Sarno P, Jope RS. Glycogen synthase kinase-3β facilitates staurosporine-and heat shock-induced apoptosis: protection by lithium. J Biol Chem. 2000;275(11):7583–7590.
   PubMed Web of Science ®Google Scholar
• Pap M, Cooper GM. Role of translation initiation factor 2B in control of cell survival by the phosphatidylinositol 3-kinase/Akt/glycogen synthase kinase 3β signaling pathway. Mol Cell Biol. 2002;22(2):578–586.
   PubMed Web of Science ®Google Scholar
• Fuster-Matanzo A, Llorens-Martín M, de Barreda EG, et al. Different susceptibility to neurodegeneration of dorsal and ventral hippocampal dentate gyrus: a study with transgenic mice overexpressing GSK3β. PLoS One. 2011;6(11):e27262.
   PubMed Web of Science ®Google Scholar
• Llorens-Martin M, Fuster-Matanzo A, Teixeira CM, et al. GSK-3β overexpression causes reversible alterations on postsynaptic densities and dendritic morphology of hippocampal granule neurons in vivo. Mol Psychiatry. 2013;18(4):451–460.
   PubMed Web of Science ®Google Scholar
• Gomez-Sintes R, Hernandez F, Bortolozzi A, et al. Neuronal apoptosis and reversible motor deficit in dominant-negative GSK-3 conditional transgenic mice. EMBO J. 2007;26(11):2743–2754.
   PubMed Web of Science ®Google Scholar
• Babu AP, Chitti S, Rajesh B, et al. In silico based ligand design and docking studies of GSK-3β inhibitors. CBIJ. 2010;10:1–12.
   Google Scholar
• De Ferrari GV, Chacon MA, Barria MI, et al. Activation of Wnt signaling rescues neurodegeneration and behavioural impairments induced by β-amyloid fibrils. Mol Psychiatry. 2003;8(2):195–208.
   PubMed Web of Science ®Google Scholar
• Macdonald A, Briggs K, Poppe M, et al. A feasibility and tolerability study of lithium in Alzheimer’s disease. Int J Geriatr Psychiatry. 2008;23(7):704–711.
   PubMed Web of Science ®Google Scholar
• Mora A, Sabio G, González-Polo RA, et al. Lithium inhibits caspase 3 activation and dephosphorylation of PKB and GSK3 induced by K + deprivation in cerebellar granule cells. J Neurochem. 2001;78(1):199–206.
   PubMed Web of Science ®Google Scholar
• Ryves WJ, Harwood AJ. Lithium inhibits glycogen synthase kinase-3 by competition for magnesium. Biochem Biophys Res Commun. 2001;280(3):720–725.
   PubMed Web of Science ®Google Scholar
• Kypta RM. GSK-3 inhibitors and their potential in the treatment of Alzheimer’s disease. Expert Opin on Ther Pat. 2005;15(10):1315–1331.
   Web of Science ®Google Scholar
• Forlenza OV, De-Paula VD, Diniz BS. Neuroprotective effects of lithium: implications for the treatment of Alzheimer’s disease and related neurodegenerative disorders. ACS Chem Neurosci. 2014;5(6):443–450.
   PubMed Web of Science ®Google Scholar
• Ghribi O, Herman MM, Savory J. Lithium inhibits Aβ-induced stress in endoplasmic reticulum of rabbit hippocampus but does not prevent oxidative damage and tau phosphorylation. J Neurosci Res. 2003;71(6):853–862.
   PubMed Web of Science ®Google Scholar
• Dunn N, Holmes C, Mullee M. Does lithium therapy protect against the onset of dementia? Alzheimer Dis Assoc Disord. 2005;19(1):20–22.
   PubMed Web of Science ®Google Scholar
• Hampel H, Ewers M, Burger K, et al. Lithium trial in Alzheimer’s disease: a randomized, single-blind, placebo-controlled, multicenter 10-week study. J Clin Psychiatry. 2009;70(6):922–931.
   PubMed Web of Science ®Google Scholar
• Tariot PN, Aisen PS. Can lithium or valproate untie tangles in Alzheimer’s disease? J Clin Psychiatry. 2009;70(6):919–921.
   PubMed Web of Science ®Google Scholar
• Ryves WJ, Dajani R, Pearl L, et al. Glycogen synthase kinase-3 inhibition by lithium and beryllium suggests the presence of two magnesium binding sites. Biochem Biophys Res Commun. 2002;290(3):967–972.
   PubMed Web of Science ®Google Scholar
• Kroczka B, Branski P, Palucha A, et al. Antidepressant-like properties of zinc in rodent forced swim test. Brain Res Bull. 2001;55(2):297–300.
   PubMed Web of Science ®Google Scholar
• Bodnar LM, Wisner KL. Nutrition and depression: implications for improving mental health among childbearing-aged women. Biol Psychiatry. 2005;58(9):679–685.
   PubMed Web of Science ®Google Scholar
• Nowak G, Szewczyk B, Pilc A. Zinc and depression. An update. Pharmacol Rep. 2005;57(6):713–718.
   PubMed Web of Science ®Google Scholar
• Gómez-Ramos A, Domínguez J, Zafra D, et al. Sodium tungstate decreases the phosphorylation of tau through GSK3 inactivation. J Neurosci Res. 2006;83(2):264–273.
   PubMed Web of Science ®Google Scholar
• Witherington J. Glycogen synthase kinase 3 (GSK-3) and its inhibitors; drug discovery and development. In: Martinez A, Castro A, Medina M, Wang B, editors. Hoboken, New Jersey: Wiley; 2006, Vol. 15. p. 281–306.
   Google Scholar
• Martinez A, Castro A, Dorronsoro I, et al. Glycogen synthase kinase 3 (GSK-3) inhibitors as new promising drugs for diabetes, neurodegeneration, cancer, and inflammation. Med Res Rev. 2002;22(4):373–384.
   PubMed Web of Science ®Google Scholar
• Patel DS, Dessalew N, Iqbal P, et al. Structure-based approaches in the design of GSK-3 selective inhibitors. Curr Protein Peptide Sci. 2007;8(4):352–364.
   PubMed Web of Science ®Google Scholar
• Zaharevitz DW, Gussio R, Leost M, et al. Discovery and initial characterization of the paullones, a novel class of small-molecule inhibitors of cyclin-dependent kinases. Cancer Res. 1999;59(11):2566–2569.
   PubMed Web of Science ®Google Scholar
• Meijer L, Skaltsounis AL, Magiatis P, et al. GSK-3-selective inhibitors derived from tyrian purple indirubins. Chem Biol. 2003;10(12):1255–1266.
   PubMedGoogle Scholar
• Witherington J, Bordas V, Gaiba A, et al. 6-Heteroaryl-pyrazolo [3, 4-b] pyridines: potent and selective inhibitors of glycogen synthase kinase-3 (GSK-3). Bioorg Med Chem Lett. 2003;13(18):3059–3062.
   PubMed Web of Science ®Google Scholar
• Zhang HC, Ye H, Conway BR, et al. 3-(7-Azaindolyl)-4-arylmaleimides as potent, selective inhibitors of glycogen synthase kinase-3. Bioorg Med Chem Lett. 2004;14(12):3245–3250.
   PubMed Web of Science ®Google Scholar
• Smith DG, Buffet M, Fenwick AE, et al. 3-Anilino-4-arylmaleimides: potent and selective inhibitors of glycogen synthase kinase-3 (GSK-3). Bioorg Med Chem Lett. 2001;11(5):635–639.
   PubMed Web of Science ®Google Scholar
• Cline GW, Johnson K, Regittnig W, et al. Effects of a novel glycogen synthase kinase-3 inhibitor on insulin-stimulated glucose metabolism in zucker diabetic fatty (fa/fa) rats. Diabetes. 2002;51(10):2903–2910.
   PubMed Web of Science ®Google Scholar
• Lo Monte F, Kramer T, Gu J, et al. Identification of glycogen synthase kinase-3 inhibitors with a selective sting for glycogen synthase kinase-3α. J Med Chem. 2012;55(9):4407–4424.
   PubMed Web of Science ®Google Scholar
• Zou H, Zhou L, Li Y, et al. Benzo [e] isoindole-1, 3-diones as potential inhibitors of glycogen synthase kinase-3 (GSK-3). synthesis, kinase inhibitory activity, zebrafish phenotype, and modeling of binding mode. J Med Chem. 2010;53(3):994–1003.
   PubMed Web of Science ®Google Scholar
• Khanfar MA, Hill RA, Kaddoumi A, et al. Discovery of novel GSK-3β inhibitors with potent in vitro and in vivo activities and excellent brain permeability using combined ligand-and structure-based virtual screening. J Med Chem. 2010;53(24):8534–8545.
   PubMed Web of Science ®Google Scholar
• Rochais C, Duc NV, Lescot E, et al. Synthesis of new dipyrrolo-and furopyrrolopyrazinones related to tripentones and their biological evaluation as potential kinases (CDKs1–5, GSK-3) inhibitors. Eur J Med Chem. 2009;44(2):708–716.
   PubMed Web of Science ®Google Scholar
• Sivaprakasam P, Han X, Civiello RL, et al. Discovery of new acylaminopyridines as GSK-3 inhibitors by a structure guided in-depth exploration of chemical space around a pyrrolopyridinone core. Bioorg Med Chem Lett. 2015;25(9):1856–1863.
   PubMed Web of Science ®Google Scholar
• Sun A, Shanmugam I, Song J, et al. Lithium suppresses cell proliferation by interrupting E2F–DNA interaction and subsequently reducing S–phase gene expression in prostate cancer. Prostate. 2007;67(9):976–988.
   PubMed Web of Science ®Google Scholar
• Graff JR, McNulty AM, Hanna KR, et al. The protein kinase Cβ–selective inhibitor, enzastaurin (LY317615. HCl), suppresses signaling through the AKT pathway, induces apoptosis, and suppresses growth of human Colon cancer and glioblastoma xenografts. Cancer Res. 2005;65(16):7462–7469.
   PubMed Web of Science ®Google Scholar
• Gaisina IN, Gallier F, Ougolkov AV, et al. From a natural product lead to the identification of potent and selective benzofuran-3-yl-(indol-3-yl) maleimides as glycogen synthase kinase 3β inhibitors that suppress proliferation and survival of pancreatic cancer cells. J Med Chem. 2009;52(7):1853–1863.
   PubMed Web of Science ®Google Scholar
• Choi SJ, Lee JE, Jeong SY, et al. 5′-Substituted indirubin-3′-oxime derivatives as potent cyclin-dependent kinase inhibitors with anticancer activity. J Med Chem. 2010;53(9):3696–3706.
   PubMed Web of Science ®Google Scholar
• Palomo V, Perez DI, Perez C, et al. 5-imino-1, 2, 4-thiadiazoles: first small molecules as substrate competitive inhibitors of glycogen synthase kinase 3. J Med Chem. 2012;55(4):1645–1661.
   PubMed Web of Science ®Google Scholar
• Collino M, Aragno M, Castiglia S, et al. Insulin reduces cerebral ischemia/reperfusion injury in the hippocampus of diabetic rats: a role for glycogen synthase kinase-3β. Diabetes. 2009;58(1):235–242.
   PubMed Web of Science ®Google Scholar
• Martinez A, Gil C, Perez DI. Glycogen synthase kinase 3 inhibitors in the next horizon for Alzheimer’s disease treatment. Int J Alzheimer’s Dis. 2011;2011:1–7.
   Google Scholar
• Boulahjar R, Ouach A, Bourg S, et al. Advances in tetrahydropyrido [1, 2-a] isoindolone (valmerins) series: potent glycogen synthase kinase 3 and cyclin dependent kinase 5 inhibitors. Eur J Med Chem. 2015;101:274–287.
   PubMed Web of Science ®Google Scholar
• Bajaj S, Asati V, Singh J, et al. 1, 3, 4-Oxadiazoles: an emerging scaffold to target growth factors, enzymes and kinases as anticancer agents. Eur J Med Chem. 2015;97:124–141.
   PubMed Web of Science ®Google Scholar
• Bax B, Carter PS, Lewis C, et al. The structure of phosphorylated GSK-3β complexed with a peptide, FRATtide, that inhibits β-catenin phosphorylation. Structure. 2001;9(12):1143–1152.
   PubMed Web of Science ®Google Scholar
• Palomo V, Soteras I, Perez DI, et al. Exploring the binding sites of glycogen synthase kinase 3. Identification and characterization of allosteric modulation cavities. J Med Chem. 2011;54(24):8461–8470.
   PubMed Web of Science ®Google Scholar